T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) Post author: Post published:March 1, 2026 Post category: Continue ReadingT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme Post author: Post published:March 1, 2026 Post category: Continue ReadingB7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
CAR-T Long Term Follow Up (LTFU) Study Post author: Post published:March 1, 2026 Post category: Continue ReadingCAR-T Long Term Follow Up (LTFU) Study
SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma Post author: Post published:March 1, 2026 Post category: Continue ReadingSUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer Post author: Post published:March 1, 2026 Post category: Continue ReadingA2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Post author: Post published:March 1, 2026 Post category: Continue ReadingSafety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Post author: Post published:March 1, 2026 Post category: Continue ReadingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. Post author: Post published:March 1, 2026 Post category: Continue ReadingStudy to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax Post author: Post published:March 1, 2026 Post category: Continue ReadingCirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
